T h e ne w e ngl a nd jou r na l o f m e dicine M edical genetics focuses on the relationship between observed phenotypes and their underlying genotypes, modes of transmission, and risks of recurrence. Expected patterns of mendelian inheritance are often used to confirm the identification of disease genes, and deviations from mendelian expectations have led to the discovery of more complicated genetic underpinnings of disease (Fig. S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). [1] [2] [3] [4] [5] [6] [7] [8] Multiple (or dual) molecular diagnoses involve more than one clinical diagnosis and more than one genetic locus ( Fig. 1) , each segregating independently.
Diagnostic whole-exome sequencing affords opportunities for providing insights into relationships between multilocus genomic variation and disease. In several studies of patient series, the occurrence of multiple molecular diagnoses in a single genome has been reported in 3.2 to 7.2% of cases in which a molecular diagnosis is made, but data on this phenomenon from large case series and on the associated clinical consequences are lacking (Table S1 in the Supplementary Appendix). [9] [10] [11] [12] [13] Here we describe a large-scale clinical analysis involving patients with multiple molecular diagnoses and an analysis of their phenotypes with the use of a structured phenotype ontology.
Me thods

Patient Population
We performed a retrospective analysis involving 7374 unrelated patients who were referred to our diagnostic laboratory for proband-only or triobased whole-exome sequence analysis between October 2011 and April 2016. Whole-exome sequencing for cancer exome analysis was not included. Our laboratory is certified by the College of American Pathologists and is in compliance with the Clinical Laboratory Improvement Amendments. The reporting of deidentified demographic and molecular data was approved by the institutional review board at the Baylor College of Medicine. Of the 101 patients who received two Panel A shows digenic inheritance of pathogenic alleles at different loci from each parent, resulting in an affected offspring. Panel B shows dual molecular diagnoses -in this case, one homozygous pathogenic variant in a recessive disease gene inherited from each carrier parent and one de novo variant that resulted in a second, independent autosomal dominant disorder. Many combinations are possible: autosomal dominant plus autosomal dominant, autosomal dominant plus autosomal recessive, autosomal dominant plus X-linked, autosomal recessive plus autosomal recessive, autosomal recessive plus X-linked, and X-linked plus X-linked. 
A Digenic Inheritance B Dual Diagnoses
Statistical Analyses
A Poisson model and an alternative model of independently occurring multiple diagnoses were applied to analyze the proportions of patients with one to four molecular diagnoses in this cohort. This modeling was performed with the use of empirical data from the observed rate of molecular diagnoses in the study cohort, which represents a referral population, rather than a primarily healthy general population. The observed proportion of patients with at least one molecular diagnosis was 28.2% (2076 of 7374), which resulted in a total of 2182 independent molecular diagnoses in 7374 cases; this yielded a mean of 0.2959 diagnoses per patient, and this value was used as the Poisson rate parameter (Section S1 in the Supplementary Appendix). For the alternative independence model, the rate of singleton diagnoses was used, and powers of this rate were used to determine expected proportions of two, three, and four molecular diagnoses. To test the observed rate of multiple molecular diagnoses, we used the frequencies from the Poisson model and the alternative independence model to determine a null hypothesis for the expected number of patients with more than one molecular diagnosis. We tested the number of multiple diagnoses observed under both models against the null hypothesis, using a binomial test to determine the overall P values (Fig. S2 in the Supplementary Appendix). Details of the variant analyses, phenotype analyses, and statistical modeling of multiple diagnoses are provided in Sections S2, S3, and S4 in the Supplementary Appendix.
R esult s
Molecular Diagnoses
Among the 7374 sequential DNA samples submitted to our clinical laboratory for probandonly (7029 patients) or trio-based (345 patients) diagnostic whole-exome sequencing between October 2011 and April 2016, a molecular diagnosis involving a mendelian disease gene related to the clinical phenotype at the time of referral was reported for 2076 patients (28.2%). Two or more molecular diagnoses were reported for 101 patients (4.9%); in total, 2182 independent molecular diagnoses were reported for 7374 referred patients.
To investigate whether the proportion of multiple molecular diagnoses in this series is similar to that expected by chance alone in a referral population, we considered two models: a Poisson model, in which it was assumed that pathogenic variants arose independently at different loci within each patient's genome, and an alternative, independence model that used the observed rate of singleton diagnosis. Under both models, the observed proportion of patients with a diagnosis who had multiple molecular diagnoses (4.9%) was significantly lower than that expected among patients with a diagnosis in a referral population (Poisson model, 14.0%; independence model, 26.4%; P<0.0001 by one-sided binomial test for both models) (Fig. S2 in the Supplementary Appendix), which suggests that pathogenic variants at multiple molecular loci are underascertained in a population of patients who are referred for diagnostic whole-exome sequencing or that they do not truly occur independently. Because these analyses are based on empirical observations from a referral population, they are limited by ascertainment bias.
Among the 101 patients with multiple diagnoses, 97 had two (dual) molecular diagnoses (Table 1) , 3 had three molecular diagnoses, and 1 had four molecular diagnoses ( Fig. 2A) . Medically actionable secondary findings 16 contributed an additional two molecular diagnoses; however, because these were considered to be incidental, they were not analyzed further. Patient age and sex were not associated with the occurrence of multiple diagnoses. The specialty of the refer-T h e ne w e ngl a nd jou r na l o f m e dicine T h e ne w e ngl a nd jou r na l o f m e dicine ring physician was medical genetics in 81.2% of cases (82 of 101), neurology in 12.9% (13 of 101), neurogenetics in 2.0% (2 of 101), allergy or immunology in 1.0% (1 of 101), and unknown for the remainder (Table S2 in the Supplementary Appendix). For 6 patients, a previous molecular diagnosis was known at the time of referral but was not believed to account for the disease phenotype in its entirety; for another 11 patients, a presumptive genetic diagnosis was available (Table S3 in the Supplementary Appendix). For 34 patients, a family history suggestive of an inherited genetic condition was reported.
Modes of Inheritance in Patients with Multiple Diagnoses
Variants in autosomal dominant disease genes were the most common pathogenic variants among patients with multiple diagnoses (112 of 207 diagnoses, 54.1%) (Fig. 2B , and Disease Phenotypes Resulting from Multilocus Variation binations of autosomal dominant and X-linked genes) were found and for whom parental samples were available, 44.7% (17 of 38) had de novo variants at both disease loci (Fig. 2D) . Maternal and paternal ages were provided for 95 and 91 patients, respectively. The mean paternal age did not differ significantly between patients with two de novo pathogenic variants and patients with no de novo pathogenic variants (35.5 and 32.8 years, respectively; P = 0.14 by two-tailed t-test) ( Table S7 in the Supplementary Appendix); the parental origin for de novo variants was not determined.
Among the 42 patients for whom parental samples were available and who had pathogenic variants in one or more autosomal recessive disease genes (53 variants in total), 28 variants (52.8%), which were found in 20 patients, were homozygous variants that were confirmed to have been inherited from two heterozygous parents. A review of cSNP data for all 27 patients with at least one diagnosis that was associated with a homozygous variant revealed 22 patients with one or more regions of absence of heterozygosity larger than 10 Mb, totaling between 54 and 610 Mb per personal genome (Table S5 in the Supplementary Appendix). Consanguinity was reported in 15 of these 22 patients, and homozygous variants in two or more autosomal recessive disease genes were reported in 36.4% (8 of 22) . The absence of heterozygosity involved multiple chromosomes in all patients, which argued against uniparental disomy. Only Patient 76 harbored 2 pathogenic variants within a single region of absence of heterozygosity. One patient (Patient 100) had homozygous variants in three autosomal recessive disease genes, each located in a different region of absence of heterozygosity. Although homozygous variants in autosomal recessive genes accounted for the majority (31 of 47, 66.0%) of diagnoses in these 22 patients who had genomic intervals of absence of heterozygosity that were larger than 10 Mb, we also found 6 de novo variants: 5 in autosomal dominant genes (in patients with a variant in an autosomal dominant gene plus a variant in an autosomal recessive gene) and 1 in an X-linked gene (in a patient with a variant in an X-linked gene plus a variant in an autosomal recessive gene), which showed that de novo variation can cause disease in patients with multiple regions of absence of heterozygosity.
A combination of copy-number variants (CNVs) and single-nucleotide variants (SNVs) contributed to multiple molecular diagnoses in 12 of 101 patients (11.9%). Three patients (Patients 47, 51, and 89) had homozygous intragenic deletions involving one to three exons (Table S5 in the Supplementary Appendix).
Phenotype Description
On the basis of clinical evaluations, blended phenotypes among patients with dual diagnoses could be divided into two major categories: dis- T h e ne w e ngl a nd jou r na l o f m e dicine tinct phenotypes, wherein individual phenotypic features were clearly attributable to only one of the two diagnoses, and overlapping phenotypes, wherein phenotypic features could be attributable to either one of the diagnoses (Fig. 3) . We hypothesized that an objective, computational analysis of phenotypic similarity could be used to quantitatively differentiate distinct and overlapping phenotypes. We devised a phenotypic similarity score to objectively quantify the degree of overlap between two sets of disease phenotypes. The similarity score was calculated by the symmetric Resnik method (see Section S4 in the Supplementary Appendix) for each of 80 pairs of disease diagnoses for which both diseases in the To assess whether an objective computational assessment of phenotypic similarity can closely model a subjective, human clinical assessment of phenotype, two physician scientists (the first two authors) independently assigned all patients with two molecular diagnoses to distinct or overlapping categories after a review of the phenotypic features that were provided in the OMIM database for each disease (Table 1) . Patients were considered to have overlapping phenotypes if one or more phenotypic features were reported in OMIM as being associated with both molecular diagnoses; patients for whom no phenotypic features were shared between molecular diagnoses were categorized as having distinct phenotypes. The physician scientists were unaware of the results of the computational phenotypic similarity analyses described above. For 77 of 92 patients (83.7%) with dual diagnoses who were included in the analysis, the category assignments were concordant between the two physician scientists. Discrepancies were resolved through a joint review of the molecular diagnoses and their respective OMIM entries for each case. Next, phenotypic similarity scores were graphed according to clinical categorization made by the physician scientists; the mean (±SD) phenotype similarity score was 0.39±0.13 (SE, 0.024) for overlapping diagnoses, as compared with 0.20±0.12 (SE, 0.018) for distinct diagnoses (Fig. 4B) . Phenotypic similarity scores for clinically categorized overlapping diagnoses were significantly greater than the scores for clinically categorized distinct diag- (Fig. 4C) .
Mode of Inheritance
B Overlapping Phenotypes
Protein-protein interaction databases and pathway databases were interrogated for physical interactions between the encoded proteins in a pair. No direct interactions between the proteins encoded by the disease loci were revealed. However, an extension of our analysis to include in silico predicted second-degree and third-degree physical interactors revealed nine dual diagnoses for which interactions were predicted (Fig. S3 in the Supplementary Appendix). Four of these pairs ranked in the top seven cases in terms of phenotypic similarity scores, a finding consistent with their proposed interaction (Fig. 4B) , and the phenotypic features in these patients could be attributed to either disease diagnosis within the overlapping disease pair and may have been more severe than that observed with either molecular diagnosis alone (intellectual disability with neurodevelopmental delay in Patients 3 and 4, seizures in Patient 27, and skin photosensitivity in Patient 78). Patients 3 and 4 shared a molecular diagnosis of the Coffin-Siris syndrome (OMIM 135900) caused by pathogenic variants in ARID1B. The second diagnoses, the KBG syndrome (OMIM 148050, ANKRD11, Patient 3) and the Wiedemann-Steiner syndrome (OMIM 605130, KMT2A, Patient 4) share features of short stature, delayed bone age, intellectual disability, and developmental delay, resulting in shared phenotypes between these two patients. No primary interactors were observed among our patients with dual diagnoses; we speculate that such interactors are more likely to be represented by a digenic inheritance model (Fig. 4B) .
Discussion
The clinical implementation of whole-exome sequencing as a molecular diagnostic assay allows interrogation of the interplay between pathogenic variants in multiple genes and the resulting complex spectrum of observed phenotypes within one patient. Our study is therefore limited by the depth and breadth of reported phenotypes of the patients whose exomes we analyzed. However, phenotype analysis with a structured phenotype ontology and an objective computational analysis supports a framework in which dual molecular diagnoses lead to either distinct or overlapping categories of disease expression at extreme ends of phenotype similarity scores. This was supported by manual assessment of cases by two physician scientists, whose category assignments were 83.7% in concor- 
Phenotypic Similarity Score
T h e ne w e ngl a nd jou r na l o f m e dicine dance with one another; this illustrates the need for more objective phenotype analysis tools.
We found multiple molecular diagnoses in 4.9% of cases in which whole-exome sequencing was informative, a frequency similar to that previously reported [9] [10] [11] [12] [13] and lower than expected on the basis of a Poisson model and an alternative model of independently occurring molecular diagnoses; this suggests that patients with multiple diagnoses are underrecognized, that the pathogenic variants in each disease gene do not occur in an independent fashion, or that there is a synthetic lethal effect. These analyses are limited by the ascertainment bias that is inherent in the study of a referral population, as well as by the circumstances leading to inclusion in or exclusion from this population and the simplicity of the epidemiologic models of mutational events within a population. Nonetheless, these findings support the notion that a diagnostic evaluation is not necessarily complete with the identification of an initial molecular diagnosis and that genomewide analyses may reveal more than one mendelian disease that is relevant for a patient and the patient's family.
Pathogenic de novo variants were found in both autosomal dominant disease genes and X-linked disease genes and were reported for both molecular diagnoses in 17 patients. Despite the presumption of pathogenic variants in recessive disease genes in families with consanguinity, six diagnoses were associated with de novo variants in patients with documented absence of heterozygosity. Other investigators have described the occurrence of de novo variants in consanguineous populations. [20] [21] [22] These findings support the hypothesis that recently arisen, private variants play a substantial role in human disease. 23 We found that 11.9% of patients (12 of 101) carried a pathogenic CNV, a frequency similar to the 9 to 11% observed for brain malformations or immunodeficiencies. 24, 25 In this and other studies, selection bias may have contributed to an underestimation of CNV contribution to disease, because arrays are often clinically indicated and ordered before whole-exome sequencing is considered; thus, the diagnostic evaluation may end with discovery of a pathogenic CNV, which precludes the identification of a second mendelian disorder.
In contrast to digenic inheritance, which requires contributing pathogenic variation at two specific loci for the manifestation of a single disease, [2] [3] [4] 26 dual molecular diagnoses represent an aggregation of independent diagnoses. The phenotypic complexity of genetic disease in persons with multiple molecular diagnoses may present a challenge to the physician. The blending of two distinct disease phenotypes in a single patient may suggest an apparently new clinical phenotype. 10 Alternatively, molecular diagnoses with two overlapping disease phenotypes may be incorrectly interpreted as the phenotypic expansion of a single disease.
Complementary to the idea of trait manifestations of more than one molecular diagnosis is the concept of mutational burden, in which variants at more than one locus associated with a particular disease result in a modified (typically more severe) disease phenotype. 8 Further support for such a mutational burden hypothesis can be observed at a single locus for dosage-sensitive genes such as PMP22, which causes more severe polyneuropathy when in quadruplicate than when in triplicate. 27 Our data indicate that bioinformatic tools and a structured ontology may be used to objectively assess complex phenotypes and that overlapping phenotypes may involve protein pairs that interact closely at the molecular level (for example, ARID1B and ANKRD11) or more distantly at the level of a functional unit or organ system, such as the eye (CRYGD and COL4A1) or brain (PLA2G6 and BCAP31). The mutational burden of the neuron as a functional unit has recently been shown to contribute to disease severity. 8 Using this same interaction analysis, we found in silico-predicted physical interactions between protein products of genes in patients with distinct phenotypes, although three of the disease pairs had phenotypic similarity scores above the mean similarity score observed for distinct cases.
Our data challenge the notion that a diagnostic investigation is necessarily complete after a single genetic diagnosis has been obtained. The phenotype of a patient with two genetic diagnoses may be influenced by the extent to which the phenotype associated with each individual disease overlaps that of the other. Our bioinformatic analysis of phenotypes focused on patients for whom only two molecular diagnoses were reported. However, as additional disease genes are defined and technologies for rare variant detection continue to improve, more cases of mul-Disease Phenotypes Resulting from Multilocus Variation tiple molecular diagnoses are likely to be identified and, in turn, to improve knowledge about the effect of multiple rare variants at more than one locus on biology and human disease.
